Condition
High Grade B Cell Lymphoma
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Not Yet Recruiting2
Enrolling By Invitation1
Recruiting1
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07735533Phase 1Not Yet Recruiting
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
NCT06765317Phase 2Recruiting
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
NCT06985576Enrolling By Invitation
Long-term Study to Evaluate Safety and Persistence of GF-CART01
NCT07463781Not Yet Recruiting
Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy
NCT02623920Phase 2Withdrawn
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Showing all 5 trials